金沙娱乐js288.com

Home > R&D > Overview

Overview

Humanwell has set up five research centers in China, the United States and Europe. In the United States, it has more than 70 approved ANDAs, more than 100-网上赌场js9001 OTC SKUs, and more than 20 drug candidates in various stages of development. The company spends approximately 5% of its revenue in research and development, which ranks it in the R&D investment group among its domestic pharmaceutical peers. Currently, Humanwell has 218 drugs in development, including 28-奥门金沙手机版官方网址-金沙娱乐j
88.com-js393.com
new drugs and 9 new chemical entities (NCEs) in various stages of clinical development.

 

 

js393.com

FAST FACTS

  • 218

    Number of candidates

    Under development

  • 37

    Number of INDs

    In clinical trial

  • 5%

    Percentage of annual

    Revenue earmarked for R&D

  • 1200+

    Number of R&D staff

     

  • 66

    Number of R&D

    Staff with Ph. D